A Decade of Interventional Radiotherapy (Brachytherapy): Progress, Challenges, and Future Prospects - A Bibliometric

Federico Mastroleo1,2,3, Ekaterina Milovanova2,3, Stefano Durante2

  • 1Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.

BackgroundInterventional radiotherapy (IRT), also known as brachytherapy, has become a cornerstone of radiation oncology due to its ability to maximize therapeutic efficacy while minimizing side effects to surrounding tissues. This bibliometric analysis aims to examine the evolution of IRT over the past decade.Material and MethodsA string comprising IRT-related keywords was developed, and data were extracted from the Scopus database for English-language documents published between January 2014 and December 2024. The analysis was performed using Bibliometrix packageResultsA total of 15 755 documents from 2150 sources were analyzed, revealing an average annual growth rate of 1.03%. Publication trends were stable from 2014 to 2018, surged from 2019, and peaked in 2021, with subsequent levels remaining above pre-2019 figures. Original articles accounted for 72.7% of the literature, with key contributions from journals such as "Brachytherapy" and the "Journal of Contemporary Brachytherapy". The analysis highlighted strong collaborative networks, with significant input from North American and European institutions, and identified focal research themes including uterine cervical cancer and prostate brachytherapy. Emerging topics, such as deep learning, artificial intelligence, and personalized dosimetry, underscore the field's shift towards precision medicine.ConclusionsThe findings reflect IRT's dynamic research landscape and its growing integration into modern oncologic practice, emphasizing the need for continued interdisciplinary efforts and clinical trials to advance this minimally invasive treatment modality further.Highlights• A decade-long bibliometric analysis of 15 755 publications on interventional radiotherapy (IRT) reveals stable growth, with a notable surge in research activity post-2019.• Uterine, cervical, and prostate cancers remain the most studied clinical indications for IRT globally.• North American and European institutions dominate collaborative networks, reflecting the strength of transatlantic research partnerships.• Emerging research themes include artificial intelligence, deep learning, and personalized dosimetry-marking a transition toward precision oncology.• The field's evolving landscape highlights the increasing clinical and scientific significance of IRT in contemporary cancer care.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...